Form 10-Q BRISTOL MYERS SQUIBB CO For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at Goldman Sachs
July 29, 2024 7:18 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $57.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "BMY's noteworthy outperformance on Friday July 26 (+~11% vs. flat XLV), while it occurred amidst favorable shifts in the broader market macro backdrop, was earned, in our... More
